We observed a delay in the myeloid leukaemia (312 days compared with 96 days) in the control, and these leukaemias relapsed with MSI2 positivity, providing evidence that MSI2 overexpression must be sustained to maintain disease. This evidence concerns the gene MSI2 and leukemia.